Abstract
Antischizophrenic neuroleptic drugs of the diphenylbutylpiperidine class, which includes pimozide, fluspirilene, penfluridol, and clopimozide, inhibit [3H]nitrendipine binding with IC50 values of 13-30 nM. This inhibition involves receptors for the verapamil/prenylamine class of calcium channel antagonists. These diphenylbutylpiperidines also inhibit potassium-induced calcium-dependent contractions of rat vas deferens at concentrations of 40-350 nM. Other phenothiazine and butyrophenone neuroleptics lack such potent calcium-antagonist actions. Diphenylbutylpiperidines also differ from other neuroleptics in their ability to relieve negative symptoms of schizophrenia, such as emotional withdrawal, as well as the positive symptoms which respond to all neuroleptics. We suggest that these unique antischizophrenic actions are related to a blockade by diphenylbutylpiperidines of voltage-operated calcium channels.
Full text
PDF



Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Crow T. J. Molecular pathology of schizophrenia: more than one disease process? Br Med J. 1980 Jan 12;280(6207):66–68. doi: 10.1136/bmj.280.6207.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Denef C., Van Nueten J. M., Leysen J. E., Janssen P. A. Evidence that pimozide is not a partial agonist of dopamine receptors. Life Sci. 1979 Jul 16;25(3):217–225. doi: 10.1016/0024-3205(79)90288-1. [DOI] [PubMed] [Google Scholar]
- Ehlert F. J., Roeske W. R., Itoga E., Yamamura H. I. The binding of [3H]nitrendipine to receptors for calcium channel antagonists in the heart, cerebral cortex, and ileum of rats. Life Sci. 1982 Jun 21;30(25):2191–2202. doi: 10.1016/0024-3205(82)90293-4. [DOI] [PubMed] [Google Scholar]
- Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977;17:149–166. doi: 10.1146/annurev.pa.17.040177.001053. [DOI] [PubMed] [Google Scholar]
- Frangos H., Zissis N. P., Leontopoulos I., Diamantas N., Tsitouridis S., Gavriil I., Tsolis K. Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatr Scand. 1978 May;57(5):436–446. doi: 10.1111/j.1600-0447.1978.tb06912.x. [DOI] [PubMed] [Google Scholar]
- Gould R. J., Murphy K. M., Snyder S. H. [3H]nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists. Proc Natl Acad Sci U S A. 1982 Jun;79(11):3656–3660. doi: 10.1073/pnas.79.11.3656. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Haas S., Beckmann H. Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatria. 1982 Mar;15(2):70–74. doi: 10.1055/s-2007-1019512. [DOI] [PubMed] [Google Scholar]
- Janssen P. A., Soudijn W., van Wijngaarden I., Dresse A. Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. 3. Regional distribution of pimozide and of haloperidol in the dog brain. Arzneimittelforschung. 1968 Mar;18(3):282–287. [PubMed] [Google Scholar]
- Kenakin T. P. The Schild regression in the process of receptor classification. Can J Physiol Pharmacol. 1982 Mar;60(3):249–265. doi: 10.1139/y82-036. [DOI] [PubMed] [Google Scholar]
- Kudo Y. A double-blind comparison of pimozide with carpipramine in schizophrenic patients. Acta Psychiatr Belg. 1972 Nov;72(6):685–697. [PubMed] [Google Scholar]
- Lapierre Y. D. A controlled study of penfluridol in the treatment of chronic schizophrenia. Am J Psychiatry. 1978 Aug;135(8):956–959. doi: 10.1176/ajp.135.8.956. [DOI] [PubMed] [Google Scholar]
- Lapierre Y. D., Lavallee J. Pimozide and the social behavior of schizophrenics. Curr Ther Res Clin Exp. 1975 Jul;18(1 Pt 2):181–188. [PubMed] [Google Scholar]
- Leedham J. A., Pennefather J. N. Dopamine acts at the same receptors as noradrenaline in the rat isolated vas deferens. Br J Pharmacol. 1982 Oct;77(2):293–299. doi: 10.1111/j.1476-5381.1982.tb09298.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- MacLeod R. M., Lamberts S. W. The biphasic regulation of prolactin secretion by dopamine agonist-antagonists. Endocrinology. 1978 Jul;103(1):200–203. doi: 10.1210/endo-103-1-200. [DOI] [PubMed] [Google Scholar]
- Miller R. J., Hiley C. R. Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature. 1974 Apr 12;248(449):596–597. doi: 10.1038/248596a0. [DOI] [PubMed] [Google Scholar]
- Murphy K. M., Gould R. J., Largent B. L., Snyder S. H. A unitary mechanism of calcium antagonist drug action. Proc Natl Acad Sci U S A. 1983 Feb;80(3):860–864. doi: 10.1073/pnas.80.3.860. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nordstrom L. A., Globel F. L. The effect of lidoflazine on exercise tolerance in patients with angina pectoris. Chest. 1978 Jul;74(1):50–54. doi: 10.1378/chest.74.1.50. [DOI] [PubMed] [Google Scholar]
- Peroutka S. J., Synder S. H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry. 1980 Dec;137(12):1518–1522. doi: 10.1176/ajp.137.12.1518. [DOI] [PubMed] [Google Scholar]
- Peroutka S. J., U'Prichard D. C., Greenberg D. A., Snyder S. H. Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain. Neuropharmacology. 1977 Sep;16(9):549–556. doi: 10.1016/0028-3908(77)90023-5. [DOI] [PubMed] [Google Scholar]
- Pinder R. M., Brogden R. N., Swayer R., Speight T. M., Spencer R., Avery G. S. Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs. 1976;12(1):1–40. doi: 10.2165/00003495-197612010-00001. [DOI] [PubMed] [Google Scholar]
- Prozialeck W. C., Weiss B. Inhibition of calmodulin by phenothiazines and related drugs: structure-activity relationships. J Pharmacol Exp Ther. 1982 Sep;222(3):509–516. [PubMed] [Google Scholar]
- Seeman P. Brain dopamine receptors. Pharmacol Rev. 1980 Sep;32(3):229–313. [PubMed] [Google Scholar]
- Shopsin B., Klein H., Gerbino L., Selzer G. Penfluridol: an open phase III study in acute newly admitted hospitalized schizophrenic patients. Psychopharmacology (Berl) 1977 Dec 19;55(2):157–164. doi: 10.1007/BF01457852. [DOI] [PubMed] [Google Scholar]
- Singh A. N. Clinical evaluation of fluspirilene as a maintenance therapy in chronic schizophrenic patients. Can Psychiatr Assoc J. 1973 Oct;18(5):415–419. doi: 10.1177/070674377301800512. [DOI] [PubMed] [Google Scholar]
- Snyder S., Greenberg D., Yamamura H. I. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 1974 Jul;31(1):58–61. doi: 10.1001/archpsyc.1974.01760130040006. [DOI] [PubMed] [Google Scholar]
- Spedding M. Assessment of "Ca2+ -antagonist" effects of drugs in K+ -depolarized smooth muscle. Differentiation of antagonist subgroups. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):234–240. doi: 10.1007/BF00500485. [DOI] [PubMed] [Google Scholar]
- West B., Dannies P. S. Antipsychotic drugs inhibit prolactin release from rat anterior pituitary cells in culture by a mechanism not involving the dopamine receptor. Endocrinology. 1979 Apr;104(4):877–880. doi: 10.1210/endo-104-4-877. [DOI] [PubMed] [Google Scholar]